Neurophth Therapeutics, a Wuhan, Shanghai, and Suzhou, China- and San Diego CA-based integrated genomic medicines company, raised USD60M in Series C funding.
The round was led by CMG-SDIC Capital and Sequoia Capital China. Additional new investors include funds and accounts managed by Sunshine Insurance and China Merchant Bank International Capital.
The company intends to use the funds to accelerate growth, progress its lead clinical program in LHON to ex-China, enrich R&D pipeline and programs through business development and continue to expand the international standard gene therapy manufacturing platform.
Led by Alvin Luk, CEO, Neurophth is a gene therapy company for ophthalmic diseases. Its most advanced investigational candidate, NR082 (NFS-01 project, rAAV2-ND4), in development for the treatment of ND4-mediated LHON, has been granted orphan drug designation (ODD) by the U.S. FDA and its IND evaluating NR082 in a Phase 1/2/3 clinical trial has also been approved by the China NMPA in March 2021 with the first patient being dosed in June 2021. The pipeline also includes ND1-mediated LHON, autosomal dominant optic atrophy, optic neuroprotection (e.g., glaucoma), vascular retinopathy (e.g., diabetic retinopathy), and five other preclinical candidates.
Neurophth has initiated the scaling up in-house manufacturing process in single-use technologies to support future commercial demand at the Suzhou facilities.
FinSMEs
23/11/2021